Skip to main content

Advertisement

Log in

Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Tumoral necrosis factor alpha blockers are very efficient in the treatment of many inflammatory systemic diseases, including rheumatoid arthritis and psoriasis. However, a paradoxical arouse of psoriasiform lesions may occur in a few patients taking anti-TNFα. The etiology of this rare side effect is still a mystery, and its treatment may be difficult. The authors report the resolution of adalimumab-induced psoriasis in a woman with rheumatoid arthritis after the use of high vitamin D3 doses for the treatment of vitamin D deficiency. This is the first report of resolution of anti-TNFα-induced psoriasiform lesions by high doses of vitamin D3 in a patient with rheumatoid arthritis and vitamin D deficiency. This case raises interesting questions on the role of vitamin D deficiency in the pathogenesis of this side effect and on the possible usefulness of high-dose vitamin D3 in its treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. (2008) Tumor necrosis factor-[alpha] inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9(1). Available from: http://adisonline.com/dermatology/Fulltext/2008/09010/Tumor_Necrosis_Factor__alpha__Inhibitor_Induced.1.aspx. [Internet]

  2. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL et al (2009) Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis Fev 68(2):209–215

    Article  CAS  Google Scholar 

  3. Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M et al (2009) Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 48(7):761–764

    Article  CAS  Google Scholar 

  4. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S et al (2007) Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 143(2):223–231

    Article  PubMed  Google Scholar 

  5. Grinblat B, Scheinberg M (2008) The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthr Rheum 37(4):251–255

    Article  Google Scholar 

  6. Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A (2009) Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 161(5):1081–1088

    Article  PubMed  CAS  Google Scholar 

  7. Adams JS, Hewison M (2010) Update in vitamin D. J Clin Endocrinol Metab 95(2):471–478

    Article  PubMed  Google Scholar 

  8. Tanghetti EA (2009) The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol 8(8 Suppl):s4–s8

    PubMed  Google Scholar 

  9. Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66(9):1137–1142

    Article  PubMed  CAS  Google Scholar 

  10. Prabhu Anand S, Selvaraj P, Narayanan PR (2009) Effect of 1, 25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis. Cytokine 45(2):105–110

    Article  PubMed  CAS  Google Scholar 

  11. Dayangac-Erden D, Karaduman A, Erdem-Yurter H (2007) Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res 299(10):487–491

    Article  PubMed  CAS  Google Scholar 

  12. Okita H, Ohtsuka T, Yamakage A, Yamazaki S (2002) Polymorphism of the vitamin D(3) receptor in patients with psoriasis. Arch Dermatol Res 294(4):159–162

    Article  PubMed  CAS  Google Scholar 

  13. Perez A, Raab R, Chen TC, Turner A, Holick MF (1996) Safety and efficacy of oral calcitriol (1, 25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 134(6):1070–1078

    Article  PubMed  CAS  Google Scholar 

  14. Huckins D, Felson DT, Holick M (1990) Treatment of psoriatic arthritis with oral 1, 25-dihydroxyvitamin D3: a pilot study. Arthr Rheum 33(11):1723–1727

    Article  CAS  Google Scholar 

  15. Gaál J, Lakos G, Szodoray P, Kiss J, Horváth I, Horkay E et al (2009) Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol 89(2):140–144

    PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no potential conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gláucio Ricardo Werner de Castro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Werner de Castro, G.R., Neves, F.S., Pereira, I.A. et al. Resolution of adalimumab-induced psoriasis after vitamin D deficiency treatment. Rheumatol Int 32, 1313–1316 (2012). https://doi.org/10.1007/s00296-011-1799-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-1799-9

Keywords

Navigation